U.S., Aug. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07758127) titled 'Updates and Insights on HER2 in Breast Cancer in Sohag Governorate' on Aug. 05.
Brief Summary: * To evaluate HER2 expression in breast carcinoma with emphasizing HER2-ultralow, and HER2-low, HER2 equivocal tumors.
* To correlate the results of HER2 with clinico-pathological prognostic parameters; examples tumor grade, Ki-67 proliferation index, nodal status, tumor size, lympho-vascular invasion, and perineural invasion, tumor infiltrating lymphocytes
* To access interobserval agreement in HER2 score interpretation
Study Start Date: Sept., 2026
Study Type: OBSERVATIONAL
Condition:
HER2 Status in Breast Cancer
Recruitment Statu...